Carpal tunnel syndrome
Red light therapy for carpal tunnel syndrome
Evidence from systematic reviews and meta-analyses on low-level laser therapy for carpal tunnel syndrome.
Cited reviews include six RCTs with 418 patients and eight RCTs with 473 patients / 631 wrists.
low
partially-replicable
Bottom line
Carpal tunnel should be framed as weak evidence for targeted clinical LLLT, not a consumer panel protocol.
Consensus: Carpal tunnel evidence is mixed and does not support strong claims; some outcomes improve, but pain/function superiority is not consistent.
What the studies found
- A 2020 network meta-analysis found limited added benefit over splinting and did not recommend LLLT addition.
- A 2017 meta-analysis found grip-strength improvement but not pain, symptom severity, or functional-status improvement.
- Overall direction is mixed and outcome-dependent.
Dosage and timing
| Wavelengths | Not settled nm |
|---|---|
| Irradiance | Not settled |
| Fluence | Not settled |
| Session time | Varied across trials. |
| Frequency | Varied across trials. |
| Duration | Varied across trials. |
| Timing | No time-of-day consensus. |
| Treatment area | Wrist/carpal tunnel region. |
| Device types | Clinical LLLT, often alongside splinting. |
| Notes | Splinting remains a common comparator and first-line conservative context. |
- No clear panel protocol emerges.
- If discussed, the protocol should be targeted wrist treatment, not whole-body exposure.
- Clinical evaluation matters because carpal tunnel involves nerve compression.
Caveats
- Numbness, weakness, or progressive symptoms need medical evaluation.
- Evidence does not justify replacing splinting or clinician-guided care.
Cited peer-reviewed sources
Cheung WKW, Wu IXY, Sit RWS, et al. Physiotherapy. 2020.
A network meta-analysis concluded LLLT plus splinting offered limited extra benefit and was not recommended for carpal tunnel syndrome management.
Bekhet AH, Ragab B, Abushouk AI, et al. Lasers in Medical Science. 2017.
A meta-analysis found grip-strength improvement but no significant pain, symptom severity, or functional-status advantage over placebo.
Last reviewed: 2026-06-15